Hepatocellular carcinoma (HCC) is an aggressive cancer that mostly affects patients with chronic liver disease and cirrhosis. Hepatocellular carcinoma is usually diagnosed late in its course; hence, the disease has a median survival of only 6 to 20 months.1 In addition to numerous surgical and interventional therapies, systemic molecularly targeted therapies and immune checkpoint inhibition form an important backbone in the treatment of HCC. Recently, the US Food and Drug Administration (FDA) approved the combination of nivolumab and ipilimumab for use in patients with HCC previously treated with sorafenib tosylate.2 In this Viewpoint, we critically appraise the evidence behind FDA drug approvals for HCC.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Desai A, Prasad V. Drug Approvals in Hepatocellular Carcinoma—Filling the Nonexistent Gap? JAMA Oncol. 2021;7(2):173–174. doi:10.1001/jamaoncol.2020.4811
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: